Clinical course and treatment details of matches for SHDT patients
UPN . | Sex/age, y . | % VH homology . | Binet stage . | Lymphocyte count higher than 50 × 109/L . | FISH karyotype . | Time to symptoms, mos . | Time to study entry, mos . | First-line therapy . | Second-line therapy . | Additional salvage therapy . | Outcome (follow-up from diagnosis) . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97021 | M/56 | 100 | C | Yes | + 12 | 85 | 114 | Clb × 22 | SHDT (Flud × 3) | No | Alive (185+) | ND |
| 98024 | F/54 | 100 | C | Yes | NA | 36 | 92 | Flud × 3 | SHDT (CHOP × 6) | No | Dead (109) | TRM |
| 98006 | M/54 | 100 | C | Yes | +12 | 73 | 78 | Clb × 2 | SHDT (Flud × 2) | No | Alive (130+) | ND |
| 2000098 | F/51 | 100 | C | Yes | NA | 18 | 18 | SHDT (CHOP × 8) | Clb × 3 | No | Dead (48) | CLL |
| 99122 | F/51 | 98.3 | C | Yes | 13q14 | 7 | 7 | SHDT (CHOP × 6) | No | No | Alive (47+) | ND |
| 98078 | F/49 | 100 | C | Yes | 11q23; t(2;13) | 1 | 3 | Clb × 4 | SHDT (CHOP × 2) | No | Alive (45+) | ND |
| 2000136 | F/48 | 100 | C | Yes | Normal | 0 | 0 | SHDT (CHOP × 3) | No | No | Alive (27+) | ND |
| 2000038 | M/57 | 100 | C | No | NA | 26 | 26 | SHDT (Flud × 3) | No | No | Alive (46+) | ND |
| 97076 | M/60 | 100 | B | Yes | 6q21; 13q14 | 24 | 83 | Clb × 31 | SHDT (CHOP × 3) | Flud × 1; CD20 × 2; prednisolone | Dead (139) | CLL |
| 99137 | M/59 | 100 | B | Yes | NA | 1 | 89 | Clb × 21 | SHDT (CHOP × 3) | No | Alive (62+) | ND |
| 2000101 | M/57 | 100 | B | Yes | Normal | 48 | 48 | SHDT (FC × 2) | No | No | Alive (66+) | ND |
| 98075 | M/56 | 100 | B | Yes | 13q14 | 3 | 3 | SHDT (CHOP × 3) | No | No | Alive (49+) | ND |
| 97099 | F/53 | 100 | B | Yes | 13q14 | 51 | 51 | SHDT (CHOP × 4) | No | No | Alive (108+) | ND |
| 97096 | F/52 | 100 | B | Yes | Normal | 1 | 38 | COP × 6 | Clb × 2 | Flud × 5; SHDT (FC × 1); FC × 1 | Dead (90) | CLL |
| 98105 | M/51 | 100 | B | Yes | 11q23; 13q14 | 7 | 15 | SHDT (CHOP × 6) | No | No | Alive (64+) | ND |
| HD006 | M/50 | 100 | B | Yes | +8q24; 11q23 | 48 | 48 | SHDT (CHOP × 3) | No | No | Alive (88+) | ND |
| 99039 | M/49 | 100 | B | Yes | 13q14 | 1 | 1 | SHDT (CHOP × 3) | No | No | Alive (43+) | ND |
| 98099 | M/49 | 98.7 | B | Yes | NA | 2 | 97 | Clb × 6 | SHDT (CHOP × 6) | No | Alive (139+) | ND |
| 230 | M/48 | 100 | B | Yes | 13q14 | 8 | 35 | Clb × 19 | SHDT (CHOP × 2) | No | Alive (112+) | ND |
| 97031 | M/56 | 100 | B | No | +12 | 2 | 2 | SHDT (CHOP × 3) | No | No | Alive (70+) | ND |
| 2000050 | M/51 | 99.2 | B | No | NA | 1 | 9 | MCP × 6 | SHDT (no) | No | Alive (26+) | ND |
| 99076 | M/47 | 100 | B | No | 11q23; 13q14 | 1 | 1 | SHDT (CHOP × 3) | No | No | Dead (13) | TRM |
| 98049 | M/40 | 100 | B | No | Normal | 13 | 13 | SHDT (CHOP × 3) | No | No | Alive (34+) | ND |
| 2000092 | M/58 | 100 | A | Yes | +12 | NA | 12 | SHDT (FC × 2) | No | No | Alive (42+) | ND |
| 98002 | M/55 | 99.5 | A | Yes | 13q14 | NA | 15 | SHDT (CHOP × 3) | No | No | Alive (61+) | ND |
| 2000064 | M/53 | 100 | A | Yes | +12 | NA | 12 | SHDT (FC × 3) | No | No | Alive (33+) | ND |
| 98025 | M/58 | 100 | A | No | 11q23; 13q14 | NA | 69 | SHDT (Flud × 2) | No | No | Alive (112+) | ND |
| 2000061 | M/54 | 100 | A | No | Normal | NA | 11 | SHDT (FC × 1) | No | No | Alive (34+) | ND |
| 99102 | F/51 | 99.1 | A | No | 11q23 | NA | 11 | SHDT (CHOP × 2) | No | No | Alive (52+) | ND |
| 2000014 | M/64 | 97.4 | C | No | NA | 18 | 18 | SHDT (CHOP × 3) | No | No | Dead (38) | Mesothelioma |
| 256 | M/51 | 94.4 | C | No | Normal | 2 | 2 | SHDT (no) | No | No | Alive (79+) | ND |
| 2001020 | M/61 | 89 | B | Yes | NA | 16 | 47 | Clb × 15 | SHDT (Flud × 6) | No | Alive (64+) | ND |
| HD003 | F/46 | 87.2 | B | Yes | 13q14 | 62 | 76 | Clb × 22 | SHDT (no) | No | Alive (123+) | ND |
| 236 | M/54 | Low | B | No | NA | NA | 2 | SHDT (no) | No | No | Alive (79+) | ND |
| 99 | F/51 | 93.5 | B | No | Normal | 2 | 44 | Clb × 13 | SHDT (no) | Flud 5; CD20 × 4; FC × 2 | Alive (139+) | ND |
| 98073 | M/51 | 93.4 | B | No | +12 | 2 | 2 | SHDT (CHOP ×3) | No | No | Alive (49+) | ND |
| 206 | M/48 | 86.1 | B | No | Normal | 3 | 3 | SHDT (CHOP × 5) | No | No | Alive (88+) | ND |
| 99119 | M/57 | 93.6 | A | Yes | Normal | 89* | 89 | SHDT (CHOP × 4) | No | No | Alive (124+) | ND |
| 238 | F/49 | 91.7 | A | Yes | 11q23 | NA | 48 | SHDT (COP × 2) | No | No | Alive (134+) | ND |
| 176 | M/57 | 92 | A | No | Normal | NA | 16 | SHDT (no) | No | No | Alive (100+) | ND |
| 2000074 | M/57 | 93.7 | A | No | 13q14 | NA | 25 | SHDT (CHOP × 3) | No | No | Alive (58+) | ND |
| 97013 | M/54 | 89.5 | A | No | NA | 3† | 3 | SHDT (no) | No | No | Dead (11) | TRM |
| 271 | M/47 | 92.9 | A | No | Normal | NA | 8 | SHDT (no) | No | No | Alive (86+) | ND |
| 98069 | M/47 | 95.2 | A | No | +12 | NA | 7 | SHDT (CHOP × 3) | No | No | Alive (62+) | ND |
UPN . | Sex/age, y . | % VH homology . | Binet stage . | Lymphocyte count higher than 50 × 109/L . | FISH karyotype . | Time to symptoms, mos . | Time to study entry, mos . | First-line therapy . | Second-line therapy . | Additional salvage therapy . | Outcome (follow-up from diagnosis) . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97021 | M/56 | 100 | C | Yes | + 12 | 85 | 114 | Clb × 22 | SHDT (Flud × 3) | No | Alive (185+) | ND |
| 98024 | F/54 | 100 | C | Yes | NA | 36 | 92 | Flud × 3 | SHDT (CHOP × 6) | No | Dead (109) | TRM |
| 98006 | M/54 | 100 | C | Yes | +12 | 73 | 78 | Clb × 2 | SHDT (Flud × 2) | No | Alive (130+) | ND |
| 2000098 | F/51 | 100 | C | Yes | NA | 18 | 18 | SHDT (CHOP × 8) | Clb × 3 | No | Dead (48) | CLL |
| 99122 | F/51 | 98.3 | C | Yes | 13q14 | 7 | 7 | SHDT (CHOP × 6) | No | No | Alive (47+) | ND |
| 98078 | F/49 | 100 | C | Yes | 11q23; t(2;13) | 1 | 3 | Clb × 4 | SHDT (CHOP × 2) | No | Alive (45+) | ND |
| 2000136 | F/48 | 100 | C | Yes | Normal | 0 | 0 | SHDT (CHOP × 3) | No | No | Alive (27+) | ND |
| 2000038 | M/57 | 100 | C | No | NA | 26 | 26 | SHDT (Flud × 3) | No | No | Alive (46+) | ND |
| 97076 | M/60 | 100 | B | Yes | 6q21; 13q14 | 24 | 83 | Clb × 31 | SHDT (CHOP × 3) | Flud × 1; CD20 × 2; prednisolone | Dead (139) | CLL |
| 99137 | M/59 | 100 | B | Yes | NA | 1 | 89 | Clb × 21 | SHDT (CHOP × 3) | No | Alive (62+) | ND |
| 2000101 | M/57 | 100 | B | Yes | Normal | 48 | 48 | SHDT (FC × 2) | No | No | Alive (66+) | ND |
| 98075 | M/56 | 100 | B | Yes | 13q14 | 3 | 3 | SHDT (CHOP × 3) | No | No | Alive (49+) | ND |
| 97099 | F/53 | 100 | B | Yes | 13q14 | 51 | 51 | SHDT (CHOP × 4) | No | No | Alive (108+) | ND |
| 97096 | F/52 | 100 | B | Yes | Normal | 1 | 38 | COP × 6 | Clb × 2 | Flud × 5; SHDT (FC × 1); FC × 1 | Dead (90) | CLL |
| 98105 | M/51 | 100 | B | Yes | 11q23; 13q14 | 7 | 15 | SHDT (CHOP × 6) | No | No | Alive (64+) | ND |
| HD006 | M/50 | 100 | B | Yes | +8q24; 11q23 | 48 | 48 | SHDT (CHOP × 3) | No | No | Alive (88+) | ND |
| 99039 | M/49 | 100 | B | Yes | 13q14 | 1 | 1 | SHDT (CHOP × 3) | No | No | Alive (43+) | ND |
| 98099 | M/49 | 98.7 | B | Yes | NA | 2 | 97 | Clb × 6 | SHDT (CHOP × 6) | No | Alive (139+) | ND |
| 230 | M/48 | 100 | B | Yes | 13q14 | 8 | 35 | Clb × 19 | SHDT (CHOP × 2) | No | Alive (112+) | ND |
| 97031 | M/56 | 100 | B | No | +12 | 2 | 2 | SHDT (CHOP × 3) | No | No | Alive (70+) | ND |
| 2000050 | M/51 | 99.2 | B | No | NA | 1 | 9 | MCP × 6 | SHDT (no) | No | Alive (26+) | ND |
| 99076 | M/47 | 100 | B | No | 11q23; 13q14 | 1 | 1 | SHDT (CHOP × 3) | No | No | Dead (13) | TRM |
| 98049 | M/40 | 100 | B | No | Normal | 13 | 13 | SHDT (CHOP × 3) | No | No | Alive (34+) | ND |
| 2000092 | M/58 | 100 | A | Yes | +12 | NA | 12 | SHDT (FC × 2) | No | No | Alive (42+) | ND |
| 98002 | M/55 | 99.5 | A | Yes | 13q14 | NA | 15 | SHDT (CHOP × 3) | No | No | Alive (61+) | ND |
| 2000064 | M/53 | 100 | A | Yes | +12 | NA | 12 | SHDT (FC × 3) | No | No | Alive (33+) | ND |
| 98025 | M/58 | 100 | A | No | 11q23; 13q14 | NA | 69 | SHDT (Flud × 2) | No | No | Alive (112+) | ND |
| 2000061 | M/54 | 100 | A | No | Normal | NA | 11 | SHDT (FC × 1) | No | No | Alive (34+) | ND |
| 99102 | F/51 | 99.1 | A | No | 11q23 | NA | 11 | SHDT (CHOP × 2) | No | No | Alive (52+) | ND |
| 2000014 | M/64 | 97.4 | C | No | NA | 18 | 18 | SHDT (CHOP × 3) | No | No | Dead (38) | Mesothelioma |
| 256 | M/51 | 94.4 | C | No | Normal | 2 | 2 | SHDT (no) | No | No | Alive (79+) | ND |
| 2001020 | M/61 | 89 | B | Yes | NA | 16 | 47 | Clb × 15 | SHDT (Flud × 6) | No | Alive (64+) | ND |
| HD003 | F/46 | 87.2 | B | Yes | 13q14 | 62 | 76 | Clb × 22 | SHDT (no) | No | Alive (123+) | ND |
| 236 | M/54 | Low | B | No | NA | NA | 2 | SHDT (no) | No | No | Alive (79+) | ND |
| 99 | F/51 | 93.5 | B | No | Normal | 2 | 44 | Clb × 13 | SHDT (no) | Flud 5; CD20 × 4; FC × 2 | Alive (139+) | ND |
| 98073 | M/51 | 93.4 | B | No | +12 | 2 | 2 | SHDT (CHOP ×3) | No | No | Alive (49+) | ND |
| 206 | M/48 | 86.1 | B | No | Normal | 3 | 3 | SHDT (CHOP × 5) | No | No | Alive (88+) | ND |
| 99119 | M/57 | 93.6 | A | Yes | Normal | 89* | 89 | SHDT (CHOP × 4) | No | No | Alive (124+) | ND |
| 238 | F/49 | 91.7 | A | Yes | 11q23 | NA | 48 | SHDT (COP × 2) | No | No | Alive (134+) | ND |
| 176 | M/57 | 92 | A | No | Normal | NA | 16 | SHDT (no) | No | No | Alive (100+) | ND |
| 2000074 | M/57 | 93.7 | A | No | 13q14 | NA | 25 | SHDT (CHOP × 3) | No | No | Alive (58+) | ND |
| 97013 | M/54 | 89.5 | A | No | NA | 3† | 3 | SHDT (no) | No | No | Dead (11) | TRM |
| 271 | M/47 | 92.9 | A | No | Normal | NA | 8 | SHDT (no) | No | No | Alive (86+) | ND |
| 98069 | M/47 | 95.2 | A | No | +12 | NA | 7 | SHDT (CHOP × 3) | No | No | Alive (62+) | ND |
UPN indicates unique patient number; M, male; SHDT, sequential high-dose therapy: cytoreduction, DexaBEAM, total body irradiation/CY + autotransplant; the cytoreductive regimen prior to DexaBEAM is given in parentheses; Clb, chlorambucil with or without prednisolone; Flud, fludarabine; ND, not dead; F, female; NA, not applicable; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; TRM, treatment-related mortality; CD20, rituximab; FC, fludarabine and cyclophosphamide; COP, cyclophosphamide, vincristine, prednisolone; MCP, mitoxantron.
B symptoms.
Leukemic pericardial involvement.